Molecular markers for the diagnosis and management of ductal carcinoma in situ

Journal of the National Cancer Institute - Monographs

Volumn , Issue 41, 2010, Pages 210-213

  Polyak, Kornelia ^a,b,c  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR 2; KI 67 ANTIGEN; MICRORNA 21; MYC PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53; TAMOXIFEN; TUMOR MARKER; TUMOR PROTEIN;

ARTICLE; BASEMENT MEMBRANE; BREAST CANCER; CANCER GROWTH; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CHROMOSOME MUTATION; COMPARATIVE GENOMIC HYBRIDIZATION; DNA METHYLATION; EPITHELIAL MESENCHYMAL TRANSITION; GENETIC ASSOCIATION; HUMAN; INTRADUCTAL CARCINOMA; MYOEPITHELIUM CELL; NONHUMAN; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR MICROENVIRONMENT; BREAST TUMOR; CANCER INVASION; CELL DIFFERENTIATION; CHEMISTRY; CHROMOSOME ABERRATION; COHORT ANALYSIS; DISEASE COURSE; EPITHELIUM; FEMALE; FOLLOW UP; FORECASTING; GENE EXPRESSION PROFILING; GENETICS; MULTICENTER STUDY (TOPIC); MULTIMODALITY CANCER THERAPY; PAGET NIPPLE DISEASE; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STATISTICS; TUMOR CELL LINE; ULTRASTRUCTURE;

BASEMENT MEMBRANE; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CELL DIFFERENTIATION; CELL LINE, TUMOR; CHROMOSOME ABERRATIONS; COHORT STUDIES; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; EPITHELIUM; FEMALE; FOLLOW-UP STUDIES; FORECASTING; GENE EXPRESSION PROFILING; GENETIC ASSOCIATION STUDIES; GENOME-WIDE ASSOCIATION STUDY; HUMANS; MULTICENTER STUDIES AS TOPIC; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TUMOR MARKERS, BIOLOGICAL;

EID: 79952202663     PISSN: 10526773     EISSN: 17456614     Source Type: Book Series    
DOI: 10.1093/jncimonographs/lgq019     Document Type: Article

References (39)

1. Polyak K. Breast cancer: origins and evolution. J Clin Invest. 2007;117(11):3155-3163.
2. Sgroi DC. Preinvasive breast cancer. Annu Rev Pathol. 2009;5:193-221.
3. Burstein HJ, Polyak K, Wong JS, Lester SC, Kaelin CM. Ductal carcinoma in situ of the breast. N Engl J Med. 2004;350(14):1430-1441.
4. Polyak K, Haviv I, Campbell IG. Co-evolution of tumor cells and their microenvironment. Trends Genet. 2009;25(1):30-38.
5. Kuerer HM, Albarracin CT, Yang WT, et al. Ductal carcinoma in situ: state of the science and roadmap to advance the field. J Clin Oncol. 2009;27(2):279-288.
6. Gauthier ML, Berman HK, Miller C, et al. Abrogated response to cellular stress identifies DCIS associated with subsequent tumor events and defines basal-like breast tumors. Cancer Cell. 2007;12(5):479-491.
7. Lu J, Guo H, Treekitkarnmongkol W, et al. 14-3-3zeta Cooperates with ErbB2 to promote ductal carcinoma in situ progression to invasive breast cancer by inducing epithelial-mesenchymal transition. Cancer Cell. 2009;16(3):195-207.
8. Fisher ER, Dignam J, Tan-Chiu E, et al. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) eight-year update of Protocol B-17: intraductal carcinoma [see comments]. Cancer. 1999;86(3):429-438.
9. Fisher ER, Land SR, Saad RS, et al. Pathologic variables predictive of breast events in patients with ductal carcinoma in situ. Am J Clin Pathol. 2007;128(1):86-91.
10. Qi L, Bart J, Tan LP, et al. Expression of miR-21 and its targets (PTEN, PDCD4, TM1) in flat epithelial atypia of the breast in relation to ductal carcinoma in situ and invasive carcinoma. BMC Cancer. 2009;9:163.
11. Sempere LF, Christensen M, Silahtaroglu A, et al. Altered microRNA expression confined to specific epithelial cell subpopulations in breast cancer. Cancer Res. 2007;67(24):11612-11620.
12. Ross JS. Multigene classifiers, prognostic factors, and predictors of breast cancer clinical outcome. Adv Anat Pathol. 2009;16(4):204-215.
13. Porter D, Lahti-Domenici J, Keshaviah A, et al. Molecular markers in ductal carcinoma in situ of the breast. Mol Cancer Res. 2003;1(5):362-375.
14. Porter DA, Krop IE, Nasser S, et al. A SAGE (serial analysis of gene expression) view of breast tumor progression. Cancer Res. 2001;61(15):5697-5702.
15. Ma XJ, Salunga R, Tuggle JT, et al. Gene expression profiles of human breast cancer progression. Proc Natl Acad Sci U S A. 2003;100(10):5974-5979.
16. Vincent-Salomon A, Lucchesi C, Gruel N, et al. Integrated genomic and transcriptomic analysis of ductal carcinoma in situ of the breast. Clin Cancer Res. 2008;14(7):1956-1965.
17. Allred DC, Wu Y, Mao S, et al. Ductal carcinoma in situ and the emergence of diversity during breast cancer evolution. Clin Cancer Res. 2008;14(2):370-378.
18. Hwang ES, DeVries S, Chew KL, et al. Patterns of chromosomal alterations in breast ductal carcinoma in situ. Clin Cancer Res. 2004;10(15):5160-5167.
19. Yao J, Weremowicz S, Feng B, et al. Combined cDNA array comparative genomic hybridization and serial analysis of gene expression analysis of breast tumor progression. Cancer Res. 2006;66(8):4065-4078.
20. Park SY, Gonen M, Kim HJ, Michor F, Polyak K. Cellular and genetic diversity in the progression of in situ human breast carcinomas to an invasive phenotype. J Clin Invest. 2010;120(2):636-644.
21. Maley CC, Galipeau PC, Finley JC, et al. Genetic clonal diversity predicts progression to esophageal adenocarcinoma. Nat Genet. 2006;38(4):468-473.
22. Chin K, de Solorzano CO, Knowles D, et al. In situ analyses of genome instability in breast cancer. Nat Genet. 2004;36(9):984-988.
23. Marusyk A, Polyak K. Tumor heterogeneity: causes and consequences. Biochim Biophys Acta Rev Canc. 2010;1805(1):105-117.
24. Russo J, Russo IH. Atlas and histologic classification of tumors of the rat mammary gland. J Mammary Gland Biol Neoplasia. 2000;5(2):187-200.
25. Boland GP, Knox WF, Bundred NJ. Molecular markers and therapeutic targets in ductal carcinoma in situ. Microsc Res Tech. 2002;59(1):3-11.
26. Behbod F, Kittrell FS, LaMarca H, et al. An intraductal human-in-mouse transplantation model mimics the subtypes of ductal carcinoma in situ. Breast Cancer Res. 2009;11(5):R66.
27. Miller F. Xenograft models of premalignant breast disease. J Mammary Gland Biol Neoplasia. 2000;5(4):379-391.
28. Miller FR, Santner SJ, Tait L, Dawson PJ. MCF10DCIS.com xenograft model of human comedo ductal carcinoma in situ [letter]. J Natl Cancer Inst. 2000;92(14):1185-1186.
29. Tait L, Dawson PJ, Wolman SR, Galea K, Miller FR. Multipotent human breast stem cell line MCF10AT. Int J Oncol. 1996;9:263-267.
30. Hu M, Yao J, Carroll DK, et al. Regulation of in situ to invasive breast carcinoma transition. Cancer Cell. 2008;13(5):394-406.
31. Tait LR, Pauley RJ, Santner SJ, et al. Dynamic stromal-epithelial interactions during progression of MCF10DCIS.com xenografts. Int J Cancer. 2007;120(10):2127-2134.
32. Allinen M, Beroukhim R, Cai L, et al. Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell. 2004;6(1):17-32.
33. Ma XJ, Dahiya S, Richardson E, Erlander M, Sgroi DC. Gene expression profiling of the tumor microenvironment during breast cancer progression. Breast Cancer Res. 2009;11(1):R7.
34. Qiu W, Hu M, Sridhar A, et al. No evidence of clonal somatic genetic alterations in cancer-associated fibroblasts from human breast and ovarian carcinomas. Nat Genet. 2008;40(5):650-655.
35. Hu M, Yao J, Cai L, et al. Distinct epigenetic changes in the stromal cells of breast cancers. Nat Genet. 2005;37(8):899-905.
36. Hu M, Peluffo G, Chen H, Gelman R, Schnitt S, Polyak K. Role of COX-2 in epithelial-stromal cell interactions and progression of ductal carcinoma in situ of the breast. Proc Natl Acad Sci U S A. 2009;106(9):3372-3377.
37. Man YG, Tai L, Barner R, et al. Cell clusters overlying focally disrupted mammary myoepithelial cell layers and adjacent cells within the same duct display different immunohistochemical and genetic features: implications for tumor progression and invasion. Breast Cancer Res. 2003;5(6):R231-R241.
38. Hilson JB, Schnitt SJ, Collins LC. Phenotypic alterations in ductal carcinoma in situ-associated myoepithelial cells: biologic and diagnostic implications. Am J Surg Pathol. 2009;33(2):227-232.
39. Toussaint J, Durbecq V, Altintas S, et al. Low CD10 mRNA expression identifies high-risk ductal carcinoma in situ (DCIS). PLoS One. 2010;5(8):e12100. doi:10.1371/journal.pone.0012100.